Cancer

Virtua Health Successfully Goes Live on Oracle Cloud with Alithya as Strategic Implementation Partner

ALPHARETTA, Ga., July 16, 2025 /PRNewswire/ - Alithya is proud to announce the successful go-live of Oracle Cloud Enterprise Resource…

5 months ago

Vivid Dx Appoints Diagnostics Veteran John Sperzel as Chief Executive Officer and Board Member

OXFORD, United Kingdom, July 16, 2025 (GLOBE NEWSWIRE) -- Vivid Dx, a precision diagnostics company transforming pathogen detection and antimicrobial…

5 months ago

CYCLACEL PHARMACEUTICALS COMMENTS ON RECENT STOCK PRICE VOLATILITY

Kuala Lumpur, Malaysia, July 16, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”),…

5 months ago

Silexion Therapeutics Announces 1-for-15 Reverse Share Split

Trading on split-adjusted basis will begin at market open on July 29, 2025. This adjustment is expected to help Silexion…

5 months ago

Onconetix and Ocuvex Therapeutics announce execution of definitive merger agreement

CINCINNATI, July 16, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”) and Ocuvex Therapeutics, Inc. (“Ocuvex”),…

5 months ago

LIXTE Biotechnology Holdings Regains Compliance with Nasdaq’s Continued Listing Requirements

PASADENA, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW),…

5 months ago

Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer

Additional complete response (CR) observed in patient with multiple tumorsConfirmed overall response rate (ORR) of 50% in patients with combined…

5 months ago

Qualigen Granted New Patents Covering 25 Countries

CARLSBAD, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company” or “Qualigen”) is announcing an…

5 months ago

Jaya Biosciences Receives Patent Notices of Allowance in Japan, China, and Singapore for Novel Methods of Treating Neurological Diseases, including Alzheimer’s, Further Strengthening its Global Intellectual Property Portfolio

- Patent allowances in Japan, China and Singapore support Jaya Biosciences’ commitment to addressing unmet needs in neurodegeneration in global…

5 months ago

Prime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation to Advance Prime Editing Treatments for Cystic Fibrosis

-- Expanded funding builds on the initial agreement to accelerate development of Prime Editors for Cystic Fibrosis (CF) -- --…

5 months ago